ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.340,57
0,65%
S&P 500
5.909,03
-1,11%
Dow Jones
42.528,36
-0,42%
Euro vs US Dollar
1,03548
0,11%
Bitcoin
96.539,05
-0,36%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Pharma Equity Group A/s (0REU)

  7. Pharma Equity Group A/s (0REU) News

0REU

Pharma Equity Group A/s (0REU)

Pharma Equity Group A/s
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:0REU
DatumZeitQuelleÜberschriftSymbolFirma
13/12/202412h21UK RegulatoryThe Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.LSE:0REUPharma Equity Group A/s
29/11/202407h45UK RegulatoryMartin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
15/11/202408h32UK RegulatoryConsolidated Interim report 1 January – 30 September 2024LSE:0REUPharma Equity Group A/s
23/10/202410h28UK RegulatoryPharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.LSE:0REUPharma Equity Group A/s
14/10/202408h17UK RegulatoryMajor shareholder announcement - Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
14/10/202407h59UK RegulatoryManagers’ transactions LSE:0REUPharma Equity Group A/s
11/10/202408h37UK RegulatoryPharma Equity Group announces successful completion of directed issue of new sharesLSE:0REUPharma Equity Group A/s
04/10/202413h52UK RegulatoryPharma Equity Group announces issuance of new shares in a direct issueLSE:0REUPharma Equity Group A/s
04/10/202409h01UK RegulatoryRegistration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rightsLSE:0REUPharma Equity Group A/s
16/08/202408h52UK RegulatoryConsolidated Interim Report 1 January – 30 June 2024LSE:0REUPharma Equity Group A/s
16/07/202410h09UK RegulatoryThe Board of Directors' decision to issue convertible loansLSE:0REUPharma Equity Group A/s
15/07/202416h22UK RegulatoryMajor shareholder announcement - Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
15/07/202416h12UK RegulatoryMajor shareholder announcement - Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
03/06/202416h17UK RegulatoryResults of extraordinary general meeting in Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
16/05/202412h35UK RegulatoryThe Board of Director's decision to issue convertible loansLSE:0REUPharma Equity Group A/s
16/05/202407h27UK RegulatoryConsolidated interim report 1 January – 31 March 2024LSE:0REUPharma Equity Group A/s
08/05/202415h16UK RegulatoryExploration of options regarding a directed capital increase at market price in Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
08/05/202410h20UK RegulatoryNotice convening the extraordinary general meeting of Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
23/04/202411h45UK RegulatoryMajor shareholder announcement - Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
16/04/202417h29UK RegulatoryPassing of the General Meeting of Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
10/04/202414h21UK RegulatoryThe Board of Director's decision to issue convertible loansLSE:0REUPharma Equity Group A/s
05/04/202411h22UK RegulatoryPharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.LSE:0REUPharma Equity Group A/s
25/03/202413h06UK RegulatoryNotice convening the annual general meeting in Pharma Equity Group A/SLSE:0REUPharma Equity Group A/s
22/03/202409h00UK RegulatoryPharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009LSE:0REUPharma Equity Group A/s
21/03/202416h32UK RegulatoryCompletion of subscription of convertible loansLSE:0REUPharma Equity Group A/s
20/03/202408h58UK RegulatoryPharma Equity Group A/S - Annual Report 2023LSE:0REUPharma Equity Group A/s
05/03/202410h11UK RegulatoryPharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).LSE:0REUPharma Equity Group A/s
07/02/202413h38UK RegulatoryCompletion of subscription of convertible loansLSE:0REUPharma Equity Group A/s
07/02/202409h46UK RegulatoryThe Board of Director's decision to issue convertible loansLSE:0REUPharma Equity Group A/s
25/01/202410h08UK RegulatoryCompletion of subscription of convertible loansLSE:0REUPharma Equity Group A/s
 Showing the most relevant articles for your search:LSE:0REU

Kürzlich von Ihnen besucht

DBI
SDXP
SDAX
COIN
AVAXUSD
Avalanche
DBI
DAX
DAX
COIN
DOGEUSD
Dogecoin
COIN
BTCUSD
Bitcoin
USOTC
BASFY
BASF (QX)
PM
XAUUSD
Gold vs US Dollar
DBI
TDXP
Tec DAX
TG
BAS
BASF
NYSE
XOM
Exxon Mobil
USOTC
BNPQY
BNP Paribas (QX)
COIN
SOLUSD
Solana
TG
RHM
Rheinmetall
NYSE
JPM
JP Morgan Chase
FX
EURJPY
Euro vs Yen
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten